Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study.
Wästerlid T, Biccler JL, Brown PN, Bøgsted M, Enblad G, Mészáros Jørgensen J, Christensen JH, Wahlin BE, Smedby KE, El-Galaly TC, Jerkeman M. Wästerlid T, et al. Among authors: wahlin be. Ann Oncol. 2018 Aug 1;29(8):1882-1883. doi: 10.1093/annonc/mdy184. Ann Oncol. 2018. PMID: 29790897 Free article. Clinical Trial. No abstract available.
Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas.
Kimby E, Östenstad B, Brown P, Hagberg H, Erlanson M, Holte H, Linden O, Johansson AS, Ahlgren T, Wader K, Wahlin BE, Delabie J, Sundström C; Nordic Lymphoma Group (NLG). Kimby E, et al. Among authors: wahlin be. Leuk Lymphoma. 2015;56(9):2598-607. doi: 10.3109/10428194.2015.1014363. Epub 2015 Mar 11. Leuk Lymphoma. 2015. PMID: 25686644 Clinical Trial.
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.
Lockmer S, Østenstad B, Hagberg H, Holte H, Johansson AS, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenhølder M, Smedby KE, Brown P, Kimby E. Lockmer S, et al. Among authors: wahlin be. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262. Online ahead of print. J Clin Oncol. 2018. PMID: 30285560
Reply to M. Sorigue et al.
Lockmer S, Østenstad B, Hagberg H, Holte H, Wahlin BE, Wader KF, Smedby KE, Brown P, Kimby E. Lockmer S, et al. Among authors: wahlin be. J Clin Oncol. 2019 Mar 20;37(9):759-760. doi: 10.1200/JCO.18.02362. Epub 2019 Feb 8. J Clin Oncol. 2019. PMID: 30735430 No abstract available.
109 results